Why is Titan Biotech falling/rising?

As of 29-Jul, Titan Biotech Ltd is currently priced at 437.15, reflecting a decrease of 3.2 points or 0.73%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 3.06% during this period. Additionally, Titan Biotech is trading below its moving averages across various time frames, indicating a bearish trend. Despite a rise in investor participation, as evidenced by a 36.14% increase in delivery volume, the company's recent financial performance has been concerning. It has reported negative results for the last three consecutive quarters, with a significant drop in profit before tax and a decline in net sales growth. The stock's valuation appears high relative to its peers, further contributing to its downward pressure.
In the broader market context, Titan Biotech's short-term performance has been notably weaker than the benchmark, with a 1-week return of -2.14% compared to the Sensex's -1.03%. Over the past year, the stock has underperformed significantly, generating a return of -23.55% while the broader market has only seen a slight decline of -0.02%. This stark contrast highlights the challenges Titan Biotech faces, including poor long-term growth prospects and a high price-to-book ratio, which may deter investors in a market that is otherwise stabilizing.